Seat­tle biotech clos­es $18M Se­ries B — and ac­quires a com­pa­ny; An­oth­er George Church alum launch­es up­start

Seat­tle biotech Cyrus Biotech­nol­o­gy an­nounced this morn­ing that it closed an $18 mil­lion Se­ries B — and land­ed an ac­qui­si­tion to boot.

The biotech, which has an in-house soft­ware pro­gram for bi­o­log­ics dis­cov­ery, ac­quired Or­thog­o­nal Bi­o­log­ics, a spin-out from the Uni­ver­si­ty of Illi­nois that fo­cus­es on us­ing “Big Da­ta” to run deep mu­ta­tion­al scan­ning on pro­teins and re­cep­tors for drug dis­cov­ery.

The fi­nanc­ing in­cludes in­vest­ments from Or­biMed Ad­vi­sors, Trin­i­ty Ven­tures, Agent Cap­i­tal, Yard Ven­tures, among oth­ers. And Se­lec­ta Bio­science, with which Cyrus is al­ready work­ing on au­toim­mu­ni­ty pro­grams, joined as a strate­gic in­vestor.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER